DNQX in the nucleus accumbens inhibits cocaine-induced conditioned place preference.
Several lines of evidence suggest that activation of both AMPA/kainate receptors and dopaminergic receptors in the nucleus accumbens may be required for psychostimulant drug induced reward. However, it has been reported that dopaminergic antagonists fail to block acquisition of conditioned place preference to cocaine. The goal of these experiments was to determine whether AMPA receptor antagonist injected into the nucleus accumbens could block conditioned place preference elicited by cocaine under conditions where dopaminergic antagonists do not inhibit acquisition of place preference. DNQX (1 microgram/0.5 microliter), injected into the nucleus accumbens just before systemic injections of cocaine (20 mg/kg i.p.) during the training sessions, attenuated the acquisition of place preference. This suggests that AMPA receptors are involved in acquisition of place preference to cocaine. By contrast, fluphenazine (2.5 micrograms/0.5 microliter), injected into the nucleus accumbens during training, did not alter cocaine-induced place preference. Analysis of locomotor activity showed that the ability of flyphenazine to inhibit cocaine-induced hyperactivity progressively decreased with each training session. These observations suggest that the failure of dopaminergic antagonists to block cocaine-induced place preference may be related to adaptations occurring following repeated exposure to these drugs. Both DNQX and fluphenazine blocked the expression of conditioned place preference in rats that had been previously trained with cocaine alone. This result suggests that both AMPA and dopaminergic receptors are involved in the expression of a conditioned place preference to cocaine.
Kaddis
F G
FG
Division of Pharmacology, College of Pharmacy, Ohio State University, Columbus 43210-1291, USA.
Uretsky
N J
NJ
Wallace
L J
LJ
D000704:Analysis of Variance; D000818:Animals; D002755:Choice Behavior / Q000187:drug effects*; D003042:Cocaine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D003216:Conditioning, Operant / Q000187:drug effects*; D005476:Fluphenazine / Q000494:pharmacology; D007267:Injections; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism*; D011810:Quinoxalines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors / Q000378:metabolism; D011954:Receptors, Dopamine / Q000378:metabolism
D011810:Quinoxalines; D018091:Receptors, AMPA; D011954:Receptors, Dopamine; C056723:FG 9041; D003042:Cocaine; D005476:Fluphenazine